Chugai Pharmaceutical Co., Ltd. · TSE:4519

Chugai Pharmaceutical — Q3 2026 Earnings Presentation

32 slides from Chugai Pharmaceutical's earnings presentation, Oct 27, 2026

  1. Slide 1: Conference on FY2026.12 Q3 Financial Results

    Conference on FY2026.12 Q3 Financial Results 27 October 2026 CHUGAI PHARMACEUTICAL CO., LTD.

  2. Slide 2: Important Reminder

    Important Reminder Forward-Looking Statements This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual resul

  3. Slide 3: Agenda

    Agenda 01 FY2026 Q3 Overview President & CEO Dr. Osamu Okuda Executive Vice President, Head of Project & FY2026 Q3 Overview of Development 02 Lifecycle Management Unit Pipeline Tsukasa Kusano FY2026 Q3 Consolidated Financial 03 Director, Executive Vice President & CFO Overview (Core) Iwaaki Taniguch

  4. Slide 4: FY2026 Q3 Overview

    FY2026 Q3 Overview President & CEO Dr. Osamu Okuda

  5. Slide 5: Executive Summary

    FY2026 Q3 Overview Executive Summary 2026 Q3 Key Financial Update Financial Overview: Recorded increased revenue and profit. Tracking (Core results for the nine months ended September 30, 2026) steadily against full year forecasts and expected Sales to exceed targets JPY 906.8bn Steady domestic and

  6. Slide 6: Topline Overview

    FY2026 Q3 Overview Topline Overview Domestic sales Increased YoY. Mainstay and new Overseas sales products grew despite the NHI 【 Billions of JPY】 drug price revisions and +49.6 penetration of generic drugs. Domestic sales Note that shipment schedule was Export unit Sales volume +15.7 +62.6 price et

  7. Slide 7: Leveraging the Drug Discovery Capabilities That Created Hemlibra

    FY2026 Q3 Overview Leveraging the Drug Discovery Capabilities That Created Hemlibra for Future Drug Discovery and Sustainable Growth Three researchers received the Lasker Award in recognition of their original concept and drug discovery technologies ✓ An original concept inspired by our desire to re

  8. Slide 8: FY2026 Q3 Overview of Development Pipeline

    FY2026 Q3 Overview of Development Pipeline Executive Vice President, Head of Project & Lifecycle Management Unit Tsukasa Kusano

  9. Slide 9: Q3 Topics (1/2)

    FY2026 Q3 Overview of Development Pipeline Q3 Topics (1/2) Approved Enspryng Thyroid eye disease (TED) (U.S.) October 2026 Prevention of relapse in MOG antibody-associated disease (Japan) (SAKIGAKE July 2026 designation) Enspryng MOG antibody-associated disease (U.S. (Priority Review granted), EU) J

  10. Slide 10: Q3 Topics (2/2)

    FY2026 Q3 Overview of Development Pipeline Q3 Topics (2/2) divarasib ESMO 2026: P3 Krascendo1 study (non-small cell lung cancer) October 2026 sefaxersen ASN: P3 IMAgINATION study (interim analysis) (IgA nephropathy) October 2026 Medical sparsentan ASN: Domestic P3 RE-021-001 study (IgA nephropathy)

  11. Slide 11: 2026: Key R&D Milestones

    FY2026 Q3 Overview of Development Pipeline 2026: Key R&D Milestones Underlined and bolded: Changes since July 24, 2026 Product Indication / Study name Progress Projects to be Alecensa Advanced or recurrent ALK fusion gene-positive solid tumors（Japan） Approved Approved Lunsumio + Polivy Relapsed or r

  12. Slide 12: Further Value Provided to Patients by Hemlibra

    FY2026 Q3 Overview of Development Pipeline Further Value Provided to Patients by Hemlibra ◼ Building on nearly a decade of efficacy and safety data across patients with various clinical backgrounds, we are developing an autoinjector to further reduce treatment burden of this drug ◼ Aiming to launch

  13. Slide 13: Divarasib: Phase 3 Krascendo 1 study

    FY2026 Q3 Overview of Development Pipeline Divarasib: Phase 3 Krascendo 1 study Previously treated KRAS G12C-mutated advanced or metastatic non-small cell lung cancer (second-line) ◼ Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of

  14. Slide 14: Projected Submissions (Phase II & Later Programs and Products)

    FY2026 Q3 Overview of Development Pipeline Projected Submissions (Phase II & Later Programs and Products) NME Line extension Filed In-house giredestrant vamikibart TECENTRIQ In-licensed (Roche) (RG6171) (RG6179) (RG7446) unresectable or Macular edema associated MSI-High colon cancer In-licensed (3rd

  15. Slide 15: Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (1/2)

    FY2026 Q3 Overview of Development Pipeline Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (1/2) Generic name/ Mode of Granted rights Development Licensee Stage Indication Progress Action to licensee code KRAS-mutated US: recurrent low-grade ⚫ Obtained approval in May 2025 u

  16. Slide 16: Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (2/2)

    FY2026 Q3 Overview of Development Pipeline Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (2/2) Generic name/ Granted Mode of Development Action Licensee rights to Stage Indication Progress ★: Changes since July 24, 2026 code licensee US: Launched ⚫ Obtained US FDA approval

  17. Slide 17: FY2026 Q3 Consolidated Financial Overview (Core)

    FY2026 Q3 Consolidated Financial Overview (Core) Director, Executive Vice President & CFO Iwaaki Taniguchi

  18. Slide 18: P/L Jan – Sep (Year on Year)

    FY2026 Q3 Consolidated Financial Overview (Core) P/L Jan – Sep (Year on Year) ◼ Domestic sales (Billions of JPY) 2025 2026 Growth Increase due to growth of mainstay products and new products, and the impact of shipment timing, despite Revenue 911.6 1,068.1 + 156.5 + 17.2% decrease due to the NHI dru

  19. Slide 19: Sales Jan – Sep (Year on Year)

    FY2026 Q3 Consolidated Financial Overview (Core) Sales Jan – Sep (Year on Year) Sales by Disease Area, Sales of Major Products, Year on Year Year on Year (Billions of JPY) ( ): Actual sales in FY2026, %: Year-on-year percentage change +112.2, +14.1% *Patient Share in Hemophilia A in Japan 2026 Q3 39

  20. Slide 20: Export of Hemlibra and Actemra to Roche

    FY2026 Q3 Consolidated Financial Overview (Core) Export of Hemlibra and Actemra to Roche (Billions of JPY) 〈Hemlibra〉 *Remaining year forecast ◼Export to Roche Expected to exceed full-year forecast, reflecting strong progress in global sales of Actemra 〈Actemra〉 20

  21. Slide 21: Operating Profit Jan – Sep (Year on Year)

    FY2026 Q3 Consolidated Financial Overview (Core) Operating Profit Jan – Sep (Year on Year) (Billions of JPY) Increase in cost of sales Overseas sales +49.6 +44.2 -51.0 Increase in various costs Increase in Domestic sales +28.5 other revenue -19.9 +62.6 Export unit Impact of price foreign +48.8 excha

  22. Slide 22: Structure of Costs and Profit by Quarter

    FY2026 Q3 Consolidated Financial Overview (Core) Structure of Costs and Profit by Quarter ◼ Year on Year (vs. 2025 Q3) (Billions of JPY) % of Revenue Cost to sales ratio: increase due to a change in product mix, etc. (% of sales for cost of sales) R&D: increase due to progress of drug discovery/earl

  23. Slide 23: Structure of Revenue by Quarter

    FY2026 Q3 Consolidated Financial Overview (Core) Structure of Revenue by Quarter (Billions of JPY) ◼ Year on Year (vs. 2025 Q3) % of Revenue Domestic sales: increase due to the growth of mainstay and new products, and the impact of shipment timing Overseas sales: increase in NEMLUVIO and Alecensa Ot

  24. Slide 24: P/L Jan – Sep (vs. Forecast)

    FY2026 Q3 Consolidated Financial Overview (Core) P/L Jan – Sep (vs. Forecast) Actual Forecast 2025 ◼ Domestic sales (Billions of JPY) 2026 2026 Mostly in line with the forecast Progress Progress* Jan - Sep Jan - Dec ◼ Overseas sales Revenue 1,068.1 1,345.0 79.4% 72.5% Favorable progress in Actemra e

  25. Slide 25: Sales Jan – Sep (vs. Forecast)

    FY2026 Q3 Consolidated Financial Overview (Core) Sales Jan – Sep (vs. Forecast) Actual Forecast 2025 Actual Forecast 2025 (Billions of JPY) 2026 2026 (Billions of JPY) 2026 2026 Progress Progress * Progress Progress * Jan - Sep Jan - Dec Jan - Sep Jan - Dec Sales 906.8 1,100.0 82.4% 73.7% Specialty

  26. Slide 26: Impact from Foreign Exchange Jan – Sep

    FY2026 Q3 Consolidated Financial Overview (Core) Impact from Foreign Exchange Jan – Sep vs. 2025 vs. 2026 2025 2026 2026 2026 2026 Actual rate Forecast rate Exchange Actual Forecast Actual rate** Market Forecast (Billions of JPY) Rate rate** rate Jan - Sep average rate Jan - Sep Jan - Sep rate*** Ja

  27. Slide 27: Financial Position as of Sep 30 (vs. 2025 Year End)

    FY2026 Q3 Consolidated Financial Overview (Core) Financial Position as of Sep 30 (vs. 2025 Year End) (Billions of JPY) Total assets 2,468.6 -94.3 2,374.3 ⚫ Increase in net working capital Total liabilities -442.9 +157.1 -285.8 Increase due to decrease in accounts payable and 2,025.7 Total net assets

  28. Slide 28: Net Cash (vs. 2025 Year End)

    FY2026 Q3 Consolidated Financial Overview (Core) Net Cash (vs. 2025 Year End) (Billions of JPY) Total ■ Operating profit after adjustments * +552.3 investment Income taxes -49.6 Operating profit * +522.6 Increase in -75.0 paid, etc. * net working Depreciation, amortization and impairment +28.7 capit

  29. Slide 29: P/L Jan – Sep (Non-core adjustment)

    FY2026 Q3 Consolidated Financial Overview (Core) P/L Jan – Sep (Non-core adjustment) Non-core items Non-core items IFRS Core (Billions of JPY) Intangible results Others results Factors affected operating profit assets ◼ Intangible assets Revenue 1,068.1 1,068.1 Sales 906.8 906.8 Amortization +1.9 Ot

  30. Slide 30: Current Status / Plan for Major Investments

    FY2026 Q3 Consolidated Financial Overview (Core) Current Status / Plan for Major Investments Planned investment ～2025 2026 2027 2028 2029 2030 2031～ Period* Investment Total amount Unit to-date Ukima plant UK3(modification): Manufacture bio drug substance 20.3 14.2 billion JPY 2024 2027 Manufacturin

  31. Slide 31: Contacts

    Contacts Corporate Communications Dept. For Media: Media Relations Group Tel： +81 (0)3-3273-0881 E-mail： pr@chugai-pharm.co.jp Person in Naoki Kouzai, Hitomi Shiobara, Atsuki Hirano, Ikue Miyazawa, charge： Kaho Izumi For Investors: Investor Relations Group Tel： +81 (0)3-3273-0554 E-mail： ir@chugai-p

  32. Slide 32: INNOVATION BEYOND IMAGINATION

    INNOVATION BEYOND IMAGINATION (i)°" CHUGAI PHARMACEUTICAL ‘A member of the Roche group

Chugai Pharmaceutical — Q3 2026 Earnings Presentation on 6ix